title: PI3K in CLL: are 2 isoforms better than 1?
authors.affiliation: UNIVERSITY OF SOUTHAMPTON.
authors.forename: Andrew J
authors.identifier: http://orcid.org/0000-0003-0667-1596
authors.initials: AJ
authors.lastname: Steele
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D058534:Class I Phosphatidylinositol 3-Kinases / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D011687:Purines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007546:Isoquinolines; D009363:Neoplasm Proteins; D011687:Purines; C586691:duvelisib; D058534:Class I Phosphatidylinositol 3-Kinases; C486018:PIK3CD protein, human